These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24022018)

  • 41. Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients.
    Rao P; McCaughan J; McCalmont M; Goldsmith CE; Hall V; Millar BC; McCann MA; Downey DG; Rendall JC; Elborn JS; Moore JE
    J Cyst Fibros; 2012 Jul; 11(4):349-52. PubMed ID: 22325689
    [No Abstract]   [Full Text] [Related]  

  • 42. [Detection and management of early Pseudomonas aeruginosa infection in patients with cystic fibrosis].
    Kernen Y; Sauty A; Roulet M
    Rev Med Suisse; 2005 Mar; 1(9):637-8, 640. PubMed ID: 15813341
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of T2R38 Receptor Polymorphisms on Pseudomonas aeruginosa Infection in Cystic Fibrosis.
    Turnbull AR; Murphy R; Behrends V; Lund-Palau H; Simbo A; Mariveles M; Alton EWFW; Bush A; Shoemark A; Davies JC
    Am J Respir Crit Care Med; 2018 Jun; 197(12):1635-1638. PubMed ID: 29481289
    [No Abstract]   [Full Text] [Related]  

  • 44. [Antibiotic therapy against Pseudomonas aeruginosa and other gram-negative bacteria in cystic fibrosis].
    Le Bourgeois M
    Arch Pediatr; 2003 Sep; 10 Suppl 2():352s-357s. PubMed ID: 14671934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG; Gembitskaia TE
    Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
    Kronborg G; Shand GH; Fomsgaard A; Høiby N
    APMIS; 1992 Feb; 100(2):175-80. PubMed ID: 1554493
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
    Woodward TC; Brown R; Sacco P; Zhang J
    J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Specific Pseudomonas immunoglobulin E antibodies in sera of patients with cystic fibrosis.
    Shen J; Brackett R; Fischer T; Holder A; Kellogg F; Michael JG
    Infect Immun; 1981 May; 32(2):967-8. PubMed ID: 6788704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of Pseudomonas aeruginosa in the pathogenesis of lung disease in cystic fibrosis: more questions than answers.
    Kerem E
    Pediatr Pulmonol Suppl; 1997; 16():265-6. PubMed ID: 9443305
    [No Abstract]   [Full Text] [Related]  

  • 50. Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Döring G; Obernesser HJ; Botzenhart K; Flehmig B; Høiby N; Hofmann A
    J Infect Dis; 1983 Apr; 147(4):744-50. PubMed ID: 6404993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of a Reduction in Susceptibility Testing for
    Ponce MC; Svendsen E; Steed L; Flume PA
    Am J Respir Crit Care Med; 2020 Jan; 201(1):114-116. PubMed ID: 31469583
    [No Abstract]   [Full Text] [Related]  

  • 52. Immunohistologic quantification of Pseudomonas aeruginosa in the tracheobronchial tree from patients with cystic fibrosis.
    Potts SB; Roggli VL; Spock A
    Pediatr Pathol Lab Med; 1995; 15(5):707-21. PubMed ID: 8597857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bacterial infection in cystic fibrosis.
    May JR; Herrick NC; Thompson D
    Arch Dis Child; 1972 Dec; 47(256):908-13. PubMed ID: 4630478
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pseudomonas infections in cystic fibrosis.
    George RH
    Arch Dis Child; 1987 May; 62(5):438-9. PubMed ID: 3111389
    [No Abstract]   [Full Text] [Related]  

  • 55. Robbins device in biofilm research.
    Kharazmi A; Giwercman B; Høiby N
    Methods Enzymol; 1999; 310():207-15. PubMed ID: 10547794
    [No Abstract]   [Full Text] [Related]  

  • 56. Host defenses in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa.
    Speert DP
    Surv Synth Pathol Res; 1985; 4(1):14-33. PubMed ID: 3927464
    [No Abstract]   [Full Text] [Related]  

  • 57. Association of interleukin-10 gene haplotypes with Pseudomonas aeruginosa airway colonization in cystic fibrosis.
    Tesse R; Cardinale F; Santostasi T; Polizzi A; Mappa L; Manca A; De Robertis F; Silecchia O; Armenio L
    J Cyst Fibros; 2008 Jul; 7(4):329-332. PubMed ID: 18093884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genome-wide study of Pseudomonas aeruginosa outer membrane protein immunogenicity using self-assembling protein microarrays.
    Montor WR; Huang J; Hu Y; Hainsworth E; Lynch S; Kronish JW; Ordonez CL; Logvinenko T; Lory S; LaBaer J
    Infect Immun; 2009 Nov; 77(11):4877-86. PubMed ID: 19737893
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prevalence of children in the UK Cystic Fibrosis Registry on long term anti-Pseudomonas aeruginosa (PA) inhaled antibiotics who become culture negative for PA and a survey of practice for discontinuing treatment.
    Gilchrist FJ; Davies B; Brodlie M
    J Cyst Fibros; 2024 Jan; 23(1):174-175. PubMed ID: 37208234
    [No Abstract]   [Full Text] [Related]  

  • 60. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides.
    Kobayashi H
    Am J Med; 1995 Dec; 99(6A):26S-30S. PubMed ID: 8585531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.